Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Needs more pills...
In case anyone has forgotten what AmnioStem is about (yes, THAT Amniostem—the one for which commercialization partnerships are now being planned, as we learned in the August 2019 update) and what it portends for the future PPS of CELZ:
https://www.marketwatch.com/press-release/creative-medical-technology-holdings-announces-superior-immune-modulatory-of-amniostem-stem-cells-compared-to-other-stem-cell-types-2018-04-04
PHOENIX, April 4, 2018 /PRNewswire/ -- Creative Medical Technology Holdings (otcqb:CELZ) announced today new data demonstrating superior immune modulatory ability of its AmnioStem™ stem cell product when compared head-to-head with bone marrow, adipose tissue, and placental tissue mesenchymal stem cells. The data, which was generated by the Company at its BioLabs research facility in San Diego, showed that AmnioStem™ cells were superior at suppressing production of inflammatory mediators such as TNF-alpha, interferon gamma, and interleukin-12 as compared to other stem cells.
"Control of molecules such as TNF-alpha represents a multi-billion dollar market. Currently drugs like Humira, Remicade, and Embrel, which are antibodies blocking the TNF-alpha pathway, have sales of over $30 billion per year," said Thomas Ichim, Ph.D, Cofounder and Chief Scientific Officer of Creative Medical Technology Holdings. "Using cells as drugs represents a more viable alternative to existing approaches because the stem cells not only reduce inflammation, but also has the ability to induce healing of injured tissue.
"We are extremely excited about our data, which positions Creative Medical Technology Holdings as a force in the autoimmune market. In addition to treatment of stroke and radiation toxicity, autoimmune diseases that may benefit from use of AmnioStem™ technology include Type 1 Diabetes, Rheumatoid Arthritis, Multiple Sclerosis, and Lupus," said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. "I am thankful for our collaborative network of scientists, scientific advisors, and intellectual property advisors, which are currently working in expanding the intellectual property portfolio surrounding this new cell type."
The AmnioStem™ stem cell is covered by an issued US Patent that was exclusively licensed from the University of California by the Company in 2016.”
OTCX back in the game with almost 1M shares on the ask. Last week was here at around .01: perhaps anticipates upward action soon in which to participate tick by tick?
On the 9th—of NEVER.
Your premise is as illogical as the one I punctured—makes ZERO sense for them to engage in any of this activity, much less publicly, unless it’s legitimate and will be shown to be so in time...
Yeah—multiple doctors go on record, placing their reputations and livelihoods on the line in a very public way—all for a scam. That’s just goofy.
Ok—but WHEN? Why would they not be eager to promote what they have in an appropriate manner?
I noticed on the last 10-Q (and I drew attention to it about a week ago), their statement that year-over-year comparative decline in PPS resulted in dilution having an ultimately anti-dilutive effect. Is this SUBTLE comment really most of the reason they’re communicating so very little? That’s is, is this an important part of their strategy?
Thanks for confirming my basic recollection
I have no interest in configuring processes to the benefit of scams—and I suspect that, with enough light shined upon the issue and an adequately compelling rhetorical presentation of the argument, the SEC and other interested federal agencies could be “shamed” into making such changes...
I have a simple answer here: market platforms should be made more modern and transparent by the inclusion of “share flags” that would clearly indicate the TRUE OS denominator in relation to any trade of a certain size (to be determined). This and other similar features MUST be in place to allow traders (and agents within the markets) to see the difference between REAL shares traded and “pseudoshares.”
I don’t think you OS math is right: I recall it being around 600M when I came onboard—so it’s basically double that now (at 1.27B). As always, I’m happy to be corrected by objectively verifiable information.
Well, we ran from about .012 (when I first discovered CELZ almost two years ago) straight to .07 in a few short months. The business fundamentals were there THEN.
Now we sit mired deeper in the muck than at least I have seen here. We have a 250M share day—only to get smashed right back down to the trips.
What’s here now that wasn’t here—at least notionally—then?
Let us also not lose sight of context:!80% efficacy would be 80%’among the “toughest of the tough” cases—those that have proven unresponsive to pharmacological interventions. Moreover, there may some potential worth mentioning among many other classes of men (who surely number in the millions in the US alone) whose “situation” is not as challenging as those of the participants in the trials...
The company has gone largely dark over the last year—which only supports such trading patterns
What’s your best guess at what a buyout for the entire portfolio would be worth in 2025–strictly your opinion?
Eager to hear your opinion, Coin, and that of other longs: do you think they sell CaverStem and/or Femcelz to finance expansion with other products, or do you think they just grow slowly and organically?
I anticipate an announcement of the paper’s acceptance for publication before it actually appears in print.
Hopefully we’re somewhere in silver WAY before 2025! I can gladly wait that long for “folding money” as the PPS...
Thanks for your concern.
Again, I’ll trust investment bankers and high-level officials in foreign governments over some stranger on a free message board. No offense
Quote: BNG Bank N.V. has provided a total of €29,254,900 (approximately USD $33,161,102) in the form of Senior Term Loans, VAT Loans, Bank Guarantees and a Working Capital Facility. ETFF, BNK Bank N.V and Nationaal Groenfonds have provided a total of €6,421,550 (approximately USD $7,278,974) in Junior Term Loans and Blue Sphere's longtime partner Helios Capital, through their Helios Energy Investments 3, L.P. has provided an equity investment totaling €3,250,000 (approximately USD $3,683,949). BlueSphere shall retain a sixty percent (60%) equity ownership stake in the project.
My money’s on the idea that the investment banks (and some national governments) know what they’re doing, understand BLSP’s business model, and believe their investment in BLSP will provide future financial returns—and that they are not, by contrast, blindly throwing 10s of millions of Euros and Dollars away on a pointless and fruitless venture that is doomed to fail and create significant financial losses for all income. Call me crazy!
OTCX back in the house (on the Ask at .0144)!
5.2M locked at $15/share: long and strong, baby!
“Seriously nasty share issues.” Not sure what that means, but OK.
Nasty share structure? In the context of companies with no commercialization and multiple billions of OS can trade in pennies, I’ll take my chances with one that has 1.3B OS and is right now on the verge of having POSITIVE earnings per share (currently up from -.0106 last Q to -.0006 in the most recently reported Q): you think that’s gonna raise a few eyebrows in this cesspool??
Why would they NOT accept it? The physicians, the associated labs, and the methodology seem solid. What else is there?
My shares haven’t been RS—what is going on?
That’s more than a 100-bagger from here....
.0012s or .12s—these things matter?!
“Pump up the volume, pump up the volume, pump up the volume—dance, dance!” (For you 90s music fans)
Yeah—because don’t you know that CEOs of almost every company put their direct numbers out for the world to see these days? (eye roll)
Not to worry—I’m sure more than a “penny player” or two will do a triple take when they see a stock with POSITIVE EPS trading in the depths of this sewer. Time will tell
And currently at essentially net zero earnings per share—and soon to be POSITIVE, I predict. What impact do you expect that to have?
Actually, my understanding is that there is a discount on the front end (something like 30% lower than the lowest PPS within the last 14 days).
Also, as I noted last week, the fact that the PPS is so low actually allows them to claim (as they did in the most recent Q) that this allows them to claim that this “dilutive action actually has an anti-dilutive effect.”
5.2M shares locked GTC @$20/PPS Long and strong!
EPIPHANY (at least for me): perhaps they are moving so slowly (to many of us) because they are not yet fully engaged in commercialization—instead they are commercializing to a small group of physicians whose main purpose is to continue gathering data from the procedures that they deliver? I don’t know enough about clinical trials in their various forms to say whether this scenario is plausible in that context—but if it is, it could explain A LOT....
Results in terms of PPS? Scary to think that this may actually BE the results...